CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinue production of Fluorognost HIV-1 IFA test kits routinely used for confirmation of HIV-1 antibody-reactive donations. Based on our current testing volume, CTS has sufficient HIV-1 IFA reagent inventory to continue performing this confirmatory test through the end of August 2019.
Check out the Communication page for the complete details on the updated IFA HIV-1 assay or by clicking the link: Communications
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...